grant
National Institutes of Health
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Source: grants.gov CFDA: 93.242 Status: posted Lifecycle: new
Eligibility
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
- State governments
- For profit organizations other than small businesses
- Small businesses
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- City or township governments
- Private institutions of higher education
- Native American tribal governments (Federally recognized)
- County governments
- Public and State controlled institutions of higher education
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Independent school districts
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments